Newlink Genetics, Lumos Pharma Enter Into Merger Pact

NewLink Genetics Corp. and Lumos Pharma enter into a definitive merger agreement, companies say in a statement.

• Under terms, NewLink will issue Lumos Pharma stockholders NewLink common stock in exchange for their shares in Lumos. Lumos Pharma stockholders will own approximately 50% of NewLink
  • Lumos Pharma will become a wholly-owned subsidiary of NewLink, and NewLink will be renamed Lumos Pharma, Inc. and will trade on Nasdaq under the symbol LUMO
  • Expected to close 1Q 2020
• Will focus initially on LUM-201 (ibutamoren), a potential oral therapy for pediatric growth hormone deficiency and other endocrine disorders
  • Merger expected to provide financial support ...